Clinical trials: In-stent Restenosis
Coronary Artery Disease, In-stent Restenosis
Safety and Efficacy of Paclitaxel Coated PTCA Balloon Catheter With a Shellac Plus Vitamin E Excipient (GENOSS® DCB) in Patients With Coronary In-stent Restenosis (ISR): A Prospective, Multi-center, Observational Study
The SFRGENISTA study aims to evaluate the long-term efficacy and safety of a paclitaxel-coated balloon catheter containing shellac and vitamin E excipients (Genoss® DCB) in patients with coronary in-stent restenosis (ISR).
- Trial name
- SFRGENISTA (NCT06104007)
- Testing
- Genoss® DCB
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease
Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries
Percutaneous coronary intervention with stent implantation is limited on the one hand by restenosis due to smooth muscle cell proliferation and on the other hand by stent thrombosis due to incomplete or not sufficient enough…
- Trial name
- NCT00732953
- Testing
- Genous stent implantation with paclitaxel-eluting balloon dilation, Genous stent implantation
- Where
- 3 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University of Ulm
Coronary Artery Disease
Diabetes Drug Eluting Sirolimus Stent Experience in Restenosis Trial
The main objective of this study is to assess the safety and effectiveness of the Sirolimus-eluting stent CYPHERTM and/or updated version in reducing angiographic in-stent late loss in de novo native coronary lesions of diabetic…
- Trial name
- DESSERT (NCT00497172)
- Testing
- CYPHER Sirolimus-eluting stent, Bx SONIC bare metal stent
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Cordis US Corp.
In-stent Restenosis
In-stent Restenosis and Pericoronary Fat Attenuation Index
This study aims to investigate the predictive value of fat attenuation index (FAI) and related radiomics characteristics of pericoronary fat in patients after percutaneous coronary intervention (PCI) for the occurrence of…
- Trial name
- NCT05512832
- Where
- China
- Volunteers
- 126 people
- Sponsor
- RenJi Hospital
Ischemic Stroke
Bare -Metal Stents and Drug -Eluting Stents in the Treatment of Patients With Vertebral Artery Ostium Stenosis
The study hypothesizes that Drug -eluting stents are more effective in preventing restenosis than Bare-metal stents after Vertebral Artery Ostium stenting
- Trial name
- NCT02197559
- Testing
- DES group, BMS group
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Xuanwu Hospital, Beijing
In Stent Restenosis
DEB vs Thin-DES in DES-ISR: Long Term Outcomes (DEB Dragon Registry)
Data regarding the usefulness of percutaneous coronary intervention (PCI) with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR) in every day clinical practice is…
- Trial name
- DEB-DRAGON (NCT04415216)
- Testing
- percutaneous coronary intervention
- Where
- 9 sites in Poland
- Volunteers
- 1,369 people
- Sponsor
- Medical University of Silesia
Coronary Restenosis
The Effects of Bindarit in Preventing Stent Restenosis
The main study objective is to assess the efficacy and safety of different bindarit dosages compared to placebo in preventing restenosis, in patients submitted to coronary stenting and using a bare metal stent (Vision BMS, by…
- Trial name
- NCT01269242
- Testing
- bindarit
- Where
- Italy
- Volunteers
- 148 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Coronary Artery Disease, Type 2 Diabetes Mellitus
Comparison Between Pioglitazone and SES With type2 DM
Drug-eluting stents have been shown to decrease restenosis, but were associated with an increased rate of death, as compared with bare-metal stents.
- Trial name
- NCT00482183
- Testing
- Pioglitazone
- Volunteers
- 38 people
- Sponsor
- Showa University
Stent Restenosis, Coronary Artery Disease
Exercise Training in Coronary Artery Disease Patients After Stenting
To determine the effect of exercise training on cardiac outcomes in coronary artery disease patients after Stenting. There is a need to develop strategies, not only to prevent restenosis but also to improve patients' functional…
- Trial name
- NCT05591365
- Testing
- Structured In-Patient and Home plan, Conventional Therapy
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Riphah International University
Coronary Heart Disease
The Comparative Study of OCT，Gemstone CT and 320-detector Row Spiral CT for Evaluating Restenosis of Coronary Artery Stent
In-stent restenosis is a major reason of coronary heart disease recurrence .Even in drug eluting stent(DES), Restenosis rate could be up to 10% in diabetes and complex lesions though it was about 3-5% in general.
- Trial name
- NCT02219594
- Testing
- CT image for patient with suspected in-stent restenosis
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xuzhou Central Hospital
Catherization
Cotavance™ Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty for Treatment of In-stent Restenosis in SFA and Popliteal Arteries
In stent restenosis in peripheral artery disease (superficial and popliteal artery) either treated with uncoated or paclitaxel coated balloons.
- Trial name
- NCT01594684
- Testing
- balloon angiolplasty - drug coated balloon (Cotavance, Medrad Inc.), drug coated balloon inflation (Cotavance, Medrad Inc.), uncoated balloon (e.g. Admiral, Medtronic)
- Where
- 6 sites in Germany
- Volunteers
- 112 people
- Sponsor
- Prof. Dr. med. Gunnar Tepe
Coronary Artery Disease, Coronary Restenosis
Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation
The purpose of the present study is to provide the first in-human safety and efficacy evaluations of systemic oral anti-proliferative Everolimus therapy compared to placebo in patients treated by bare metal stents for significant…
- Trial name
- NCT00426049
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 484 people
- Sponsor
- German Heart Institute
PERIPHERAL VASCULAR DISEASE
Study Comparing Two Methods of Expanding Stents Placed in Legs of Diabetics With Peripheral Vascular Disease
Despite recent advances in stent technology and its widespread application in the treatment of peripheral vascular disease (PVD), incidences of partial or complete blockage of stent lumen (in-stent restenosis) due to in growth of…
- Trial name
- COBRA (NCT00827853)
- Testing
- Conventional angioplasty balloon, cryoplasty balloon
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- North Texas Veterans Healthcare System
Stents, Coronary Artery Disease
SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
This study is divided into 5 arms: 1. Randomized Clinical Trial (RCT): Prospective, randomized, active-controlled, single blind, parallel two-arm multi-center clinical trial in the United States (US) comparing XIENCE V®…
- Conditions
- Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis
- Trial name
- NCT00180479
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 65 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- Abbott Medical Devices
Stent Restenosis, Stent Thrombosis
veRy Thin Stents for Patients With Left mAIn or bifurcatioN in Real Life: the RAIN a Multicenter Study
For permanent coronary stents, reduction of thickness of struts have become one of the most important innovation, being related to easier manipulation, reduced risk of stent thrombosis and low rate of revascularization.
- Conditions
- Stent Restenosis, Stent Thrombosis, Left Main Coronary Artery Disease, Coronary Bifurcations
- Trial name
- RAIN (NCT03544294)
- Testing
- Xience alpine, ultimaster, resolute onyx, synergy
- Where
- Italy
- Volunteers
- 2,800 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Acute Coronary Syndrome
Comparison of Stent Graft, Sirolimus Stent, and Bare Metal Stent Implanted in Patients With Acute Coronary Syndrome
During the 6-month period 119 patients with acute coronary syndrome, were randomized to either stent graft group (n=40), sirolimus eluting stent group (n=39), or bare metal stent group (n=40).
- Trial name
- NCT00452517
- Testing
- Percutaneous Coronary Intervention
- Where
- Croatia
- Volunteers
- 100 people
- Sponsor
- University of Zagreb
Coronary Restenosis
Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis Lesions
Use of SeQuent® Please drug coated balloon (DCB) is effective to treat patients with in-stent restenosis (ISR). However, whether the type of pre-dilatation balloon prior to DCB dilatation impacts on clinical and angiographic…
- Trial name
- ELEGANT (NCT02300454)
- Testing
- Non-slip element balloon (NSE), Balloon
- Where
- 2 sites in Japan
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Mitsui Memorial Hospital
Coronary Artery Disease
The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial
To demonstrate the equivalency in in-segment late lumen loss at 8 months between the Endeavor Drug Eluting Coronary Stent System coated with ABT-578 (10 micrograms/mm) and the Cypher Sirolimus-Eluting Coronary Stent System for…
- Trial name
- ENDEAVOR III (NCT00217256)
- Testing
- Percutaneous Coronary Stenting
- Volunteers
- 436 people
- Sponsor
- Medtronic Vascular
In-stent Restenosis
CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
The goal of this first in human study is to assess the safety and inhibition of restenosis of the CVT Everolimus-coated PTCA Catheter in the treatment of subjects presenting in-stent restenotic lesions in native coronary arteries.
- Trial name
- NCT05731700
- Testing
- Drug Eluting Balloon
- Where
- 9 sites in France, Georgia and 2 more
- Volunteers
- 51 people
- Sponsor
- Abbott Medical Devices
In-stent Coronary Artery Restenosis
Intra-stent Tissue Evaluation Within BMS and DES > 3 Years Since Implantation
This study aims to test the hypothesis that plaque composition differs within a stent between bare metal stents and drug eluting stents (DES).
- Trial name
- NCT01835301
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medstar Health Research Institute